<DOC>
	<DOC>NCT01065935</DOC>
	<brief_summary>To evaluate the efficacy and safety of ALN-RSV01 plus standard of care in RSV infected lung transplant patients</brief_summary>
	<brief_title>Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Single or bilateral lung transplant recipients Confirmed RSV infection Greater than 90 days post current lung transplant Rejection free for a minimum of 30 days Known viral, bacterial, or fungal respiratory coinfection at the time of RSV diagnosis Bronchiolitis obliterans syndrome (BOS) Grade 3 or any BOS with FEV1 that has not been stable for at least 3 months Use of alemtuzumab within 9 months prior to screening, antithymocyte globulin (ATG) within 90 days of screening or prednisone or equivalent as maintenance therapy Active treatment for acute graft rejection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>ALN-RSV01</keyword>
	<keyword>RSV</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
</DOC>